Clesacostat

N/A

Report date: 2025/12/02 15:16:17
NME

Base Information

Drug NameClesacostat
Drug Alias NamePF-5221304PF-05221304
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAcetyl-CoA carboxylase inhibitors
TargetsAcetyl-CoA carboxylase
Therapy Area/IndicationsLiver CirrhosisHepatic InsufficiencyMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesColumbia University
Active IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A